ExoVasc® PEARS

Tal Golesworthy marks the ninth anniversary of receiving his PEARS implant

Today marks nine years since Tal Golesworthy became the first patient to receive a PEARS implant. Nine years on, Tal’s aorta is entirely dimensionally stable and requires no drug therapy. Since Tal’s operation a further 34 patients have received the PEARS implant, giving a collective 143 post operative patient years and with no device related deaths or other problems.

A new, innovative procedure is a big step forward for patients with an enlarged aorta

Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support

Interested in our patient experiences?

We develop medical devices that manage aortic dilatation and minimise the risk of aortic dissection.

quick links

statements & policies

Our contact details

The staff of Exstent Limited are not medically qualified and are thus not able to provide clinical advice or answer questions of a clinical nature. We may direct your attention to publications in peer-reviewed journals that provide clinical information or provide information based upon personal experience. However, for any questions of a clinical nature patients are recommended to consult a qualified clinician.